Mainovate

Mainovate is a German biotechnology company specializing in the development of antigen-specific immunotherapies for autoimmune and inflammatory disorders. Spun out from the University Medical Center Mainz, the company leverages proprietary technology to induce immune tolerance, specifically targeting conditions like Multiple Sclerosis. Their approach aims to reprogram the immune system to stop attacking self-antigens, such as myelin components, without compromising the body's ability to fight infections. By focusing on precision immune modulation, Mainovate seeks to transform the treatment landscape for patients with chronic autoimmune diseases. The company is currently in the pre-clinical stage, advancing its lead program toward clinical trials.